This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
This is a web analytics service.
Processing company
  • Zoom Analytics Ltd.
  • Petah Tikva, Israel
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
Towards a New EU Falsified Medicines Directive
06. February 2019.

Hemofarm has already been supplying pharmaceuticals in line with the upcoming EU regulation

After three years of intensive work and an investment worth about five million euros, Hemofarm is readily waiting for the EU Falsified Medicines Directive to take effect on 9th of February. The regulation, which will be binding on all EU market pharmaceutical supply chain participants as of the specified date, will protect manufacturers and patients from falsified medicines which are dispensed on prescription.

‘Not only that Hemofarm is 100 percent ready for the application of this regulation, but it has already been supplying the European Union predominantly with medicines which meet the requirements of this Directive to contain a unique identifier and a tamper-proof security seal. EU market is one of the most significant markets for us and we are therefore willing to invest several-year-long effort in the application of the required standards’, Ronald Seeliger, Hemofarm’s Chief Executive Officer, said regarding this matter.

The use of falsified medicines represents a major threat to the public health. By the Falsified Medicines Directive (FMD), the European Union introduces the system for tracking legitimate medicines from manufacturers to patients. Manufacturers will be obliged to apply safety features to each pack, which will be previously authenticated. These identification data will be stored in a database managed by the European Medicines Verification Organisation, and their authenticity will be checked in pharmacy by 2D barcode scanning.

The total investment of Hemofarm in the implementation of the system required by the relevant EU Directive amounts to approximately five million euros and refers to the procurement of the required equipment and servers. Hemofarm currently has 2,662 FMD-relevant products, and it has been packing all these products in line with the new regulation since 1st of January this year.

More about Falsified Medicines Directive (FMD)

EU passed the Falsified Medicines Directive in 2016 for the purpose of preventing primarily patients, as well as manufacturers, from falsified medicines. The regulation encompasses Rx medicines (prescription medicines), as well as all other medicines the manufactures want to protect for whatever reason. EU has given a three-year deadline to our industry for implementing the solution that will enable the application of safety features to cartons. The system implementation costs are borne by pharmaceutical manufacturers.

The Directive refers to EU market exclusively, with the exception of Greece, Italy and Switzerland (although not an EU member state, it has the access to the single market), which are given the grace period till 9 February 2025. The market of Serbia and other markets of the neighbouring non-EU member countries, are not encompassed by this regulation, but the manufacturers from these countries are obliged to observe it if they want to export to EU countries.

Through this regulation, EU keeps unique records of all unique numbers in a particular central repository (EU hub) which is shared with the National Medicines Verification Organization (NMVO) of each EU member country. Only authorized manufacturers are allowed to input data on serial numbers of medicines to the EU repository. As pharmacies in EU will be connected with the relevant country’s NMVO, when dispensing a medicine, a pharmacist will scan a code which is immediately authenticated in the database of the relevant country’s NMVO, and the feedback on medicine authenticity is received instantly.